RNA therapy targets hard-to-reach bone marrow cancer cells
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
RNA therapy targets hard-to-reach bone marrow cancer cells
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
RNA therapy targets hard-to-reach bone marrow cancer cells.
RNA therapy is emerging as a promising cancer treatment, but some types of cancer do not respond well to the therapy. Now, scientists at Tel Aviv University have demonstrated a way to treat multiple myeloma using RNA drugs.
Multiple myeloma is a cancer that affects a patient’s plasma cells. When these important immune cells become cancerous, they accumulate in the bone marrow, causing pain and immune problems. While the disease can be managed, there is currently no cure, mainly because it is difficult to get drugs to the tumors inside the patient’s bone.
In the new study, researchers in Tel Aviv demonstrate a promising new technique. It involves an RNA-based drug, part of an area of cancer-fighting that is beginning to gain traction. The drug’s active ingredient is a molecule called a small interfering RNA (siRNA), which inhibits the action of a target gene, preventing it from making a protein.
In this case, the RNA’s target gene is CKAP5, and without the corresponding protein, the cells can no longer divide. To ensure that this deadly effect only applies to cancer, the drug-carrying lipid nanoparticles are coated with antibodies that lock onto structures only on multiple myeloma cancer cells.
The Tel Aviv research team tested the technique on multiple myeloma cancer cells with several different structures. In a batch of lab-grown cells, the nanoparticles wiped out about 90 percent of the cells. They then tested the therapy on cancer cells from multiple myeloma patients, successfully eradicating 60 percent of the cancer cells. Finally, they injected the drug into mice with the disease, and as a result, about 66% of the cancer cells were eliminated, and the symptoms of the mice were also significantly improved.
While there is still much work to be done before it can be tested in humans, the team says these early results are promising.
“The drug delivery system we developed is the first to specifically target cancer cells within the bone marrow and the first to show that silencing Expression of the CKAP5 gene can be used in a system that kills blood cancer cells.
The research was published in the journal Advanced Science.
RNA therapy targets hard-to-reach bone marrow cancer cells.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
